作者
Sophie Périé, Capucine Trollet, Vincent Mouly, Valérie Vanneaux, Kamel Mamchaoui, Belaïd Bouazza, Jean Pierre Marolleau, Pascal Laforêt, Françoise Chapon, Bruno Eymard, Gillian Butler-Browne, Jérome Larghero, Jean Lacau St Guily
发表日期
2014/1/1
期刊
Molecular Therapy
卷号
22
期号
1
页码范围
219-225
出版商
Elsevier
简介
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant genetic disease mainly characterized by ptosis and dysphagia. We conducted a phase I/IIa clinical study (ClinicalTrials.gov NCT00773227) using autologous myoblast transplantation following myotomy in adult OPMD patients. This study included 12 patients with clinical diagnosis of OPMD, indication for cricopharyngeal myotomy, and confirmed genetic diagnosis. The feasibility and safety end points of both autologous myoblast transplantation and the surgical procedure were assessed by videoendoscopy in addition to physical examinations. Potential therapeutic benefit was also assessed through videoendoscopy and videofluoroscopy of swallowing, quality of life score, dysphagia grade, and a drink test. Patients were injected with a median of 178 million myoblasts following myotomy. Short and long-term (2 years) safety and …
引用总数
201420152016201720182019202020212022202320248181817132013172474
学术搜索中的文章